Table 2.
Body composition during growth hormone treatment in a pilot study of the effects of low-dose growth hormone in HIV-infected men with fat accumulation.
| Method, measure | Baseline | Month 1 of therapy | Month 6 of therapy | Pa |
|---|---|---|---|---|
| Dual energy x-ray absorptiometry, mean kg ± SD | ||||
| Total body fat | 19.0 ± 3.9 | 17.5 ± 3.2 | 16.3 ± 4.8b | .04 |
| Trunk fat | 12.9 ± 2.0 | 11.8 ± 2.1 | 10.7 ± 2.9b | .04 |
| Appendicular fat | 5.2 ± 1.6 | 4.8 ± 0.9 | 4.8 ± 1.6 | .42 |
| Lean body mass | 59.8 ± 4.2 | 61.1 ± 4.8 | 63.6 ± 5.4b | .008 |
| Abdominal CT, mean cm2 ± SD | ||||
| Visceral fat | 197.7 ± 107.0 | … | 162.0 ± 83.7 | .20 |
| Subcutaneous fat | 185.0 ± 14.8 | … | 170.6 ± 44.1 | .38 |
a
P values were obtained using repeated measures analysis of variance for values (for fat and lean body mass) at baseline, month 1, and month 6 of therapy and paired t test for values (visceral and subcutaneous fat area) at baseline and month 6 of therapy.
b
P < .05, compared with baseline, by Student-Newman-Keuls test.